Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO
TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd.
GlobeNewsWire9/24/2026Neutral
QNTM
Quantum BioPharma Ltd.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$24.75M
P/E Ratio
—
EPS
$-4.49
Beta
0.45
52W High
$19.30
52W Low
$2.07
50-Day MA
$3.28
200-Day MA
$4.59
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Quantum BioPharma Ltd.
Quantum BioPharma Ltd. (QNTM) is an innovative biotechnology company focused on advancing transformative therapies for oncology and autoimmune diseases. With a robust pipeline of biopharmaceutical products, QNTM is committed to utilizing cutting-edge research and development to address critical unmet medical needs in these therapeutic areas. The company's strategic partnerships and experienced leadership position it to successfully navigate the complexities of the biopharmaceutical landscape. As the demand for groundbreaking therapeutics rises, Quantum BioPharma presents a strong investment opportunity for institutional investors seeking exposure to the dynamic healthcare sector.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-11.78M |
| Operating Margin | 0.00% |
| Return on Equity | -621.00% |
| Return on Assets | -51.80% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.05 |
| Price-to-Book | 3.91 |
| Price-to-Sales (TTM) | 91.86 |
| EV/Revenue | 98.56 |
| EV/EBITDA | -1.57 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $6.43M |
| Float | $7.63M |
| % Insiders | 8.40% |
| % Institutions | 9.61% |
Historical Volatility
HV 10-Day
57.01%
HV 20-Day
74.61%
HV 30-Day
89.27%
HV 60-Day
79.70%
HV Rank
—
Volatility is currently contracting
Latest News
Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target
TORONTO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd.
GlobeNewsWire9/17/2026Neutral
Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto
Toronto, Ontario--(Newsfile Corp. - September 15, 2026) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (FSE: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, announces is pleased to announce its participation in the upcoming 3rd Annual ArcStone-Kingswood Growth Summit in Toronto, taking place on September 16, 2026, at the Sheraton Center Toronto Hotel.
Newsfile Corp9/15/2026Neutral
NetworkNewsAudio Announces Audio Press Release (APR) Discussing FDA Clearance for Trial of First-in-Class Treatment Creating ‘Rare Moment' in MS Research
AUSTIN, Texas, Sept. 14, 2026 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach,” featuring Quantum BioPharma Ltd . (NASDAQ: QNTM).
GlobeNewsWire9/14/2026Neutral
Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials
NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork ), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
GlobeNewsWire9/11/2026Neutral
Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment
NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Quantum BioPharma Ltd.
GlobeNewsWire9/9/2026Neutral
Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
GlobeNewsWire9/1/2026Neutral
Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial
TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum" or the "Company"), has reported its financial and operational results for the second quarter of 2026, ended June 30, 2026.
GlobeNewsWire8/14/2026Neutral
Quantum BioPharma Announces Closing of Debt Settlement
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
GlobeNewsWire7/30/2026Neutral
Quantum BioPharma Announces Intention to Settle Debt
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
GlobeNewsWire7/20/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on QNTM and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/26/2026